Skip to main content

Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Aetna CEO

Former Aetna Chairman and CEO Mark Bertolini says investors currently are trading "on a basis that says, 'does this drug work today? Did this trial pass today?''"
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.